CVS Caremark Preferred Pharmacy vs. Independent Pharmacy Under Medicare Part D: The $896-a-Year Difference on Eliquis and Jardiance in 2026
The Decision You're Facing Before October 15
If you're managing a chronic condition on Medicare — say, atrial fibrillation and type 2 diabetes — you're probably filling Eliquis and Jardiance every month without giving much thought to where you fill them. You assume that as long as the pharmacy is "in-network," the price is the price.
It isn't. And the reason why just became a bipartisan political target in a way almost nothing else in Medicare has.
A recent KFF Health News investigation into pharmacy benefit managers (PBMs) laid out something worth understanding before Medicare's Annual Enrollment Period opens on October 15: the company that decides your drug's tier placement and network pricing — the PBM — is very often the same company that owns the pharmacy it's steering you toward. CVS Caremark, the PBM arm of CVS Health, is the textbook case: it prices formularies and pharmacy networks for the same corporate parent that owns CVS retail pharmacies. Arkansas and Tennessee have already passed laws barring PBMs from owning the retail pharmacies they route patients to, and a similar bill at the federal level has picked up sponsors from both parties — a rare alignment between business-friendly Republicans and Democrats who've spent years pushing drug-pricing reform.
This matters to your wallet right now, not just as policy trivia. It determines whether your Eliquis copay is $47 or $122 this month, and it's a decision you're implicitly making every time you pick up a bottle.
What "PBM Self-Dealing" Actually Means at the Pharmacy Counter
Every standalone Part D plan and every Medicare Advantage plan with drug coverage contracts with a PBM to build its formulary — the list of covered drugs, their tiers, and the pharmacies where you get the best price. Within that formulary, plans designate certain pharmacies as "preferred" (lower copay) and others as "standard" or "non-preferred" (higher copay, but still technically in-network).
The problem the KFF investigation highlights: when the PBM setting those preferred-pharmacy designations is owned by the same parent company as one of the pharmacy chains in the network, the "preferred" pharmacy tends to be a company store. CVS Caremark PDPs disproportionately name CVS pharmacies as preferred. Optum Rx-administered plans lean toward Optum-affiliated fill options. The independent pharmacy down the street from you, or the regional chain that's actually closer to your house, gets classified as standard — and you pay more for the identical NDC-coded drug, filled the same day, at the same tier.
This is the same kind of algorithmic cost-shifting flagged in a separate Healthcare Dive report on AI-driven billing tools, where insurers and billing companies are now publicly disputing whether automation in claims processing adds costs or strips them out. PBMs increasingly use similar automated logic to set real-time tier and network placement — and just like in the billing dispute, whoever controls the algorithm controls where the savings land.
The Worked Example: Same Plan, Same Drugs, Different Pharmacy
Here's the math, using national average cost-sharing structures for Tier 3 brand drugs under a CVS Caremark-administered Part D plan in 2026.
| Drug | Preferred Pharmacy Copay/Month | Non-Preferred Pharmacy Copay/Month | Monthly Difference |
|---|---|---|---|
| Eliquis 5mg | $47 | $122 | $75 |
| Jardiance 25mg | $45 | $110 | $65 |
| Combined regimen | $92 | $232 | $140 |
Run that across 12 months:
- Filling at the preferred (CVS-owned) pharmacy: $92 × 12 = $1,104 for the year. This stays under the 2026 Part D out-of-pocket cap, so it never triggers catastrophic coverage — you simply pay $1,104, full stop.
- Filling at a non-preferred but still in-network independent pharmacy: $232 × 12 = $2,784 on paper. But the 2026 Inflation Reduction Act cap limits total out-of-pocket drug spending to $2,000. At $232/month, cumulative spending crosses $2,000 around month nine — so the beneficiary pays $2,000 total, then $0 for the rest of the year.
Net result: the exact same two drugs, same plan, same formulary tier, cost $896 more per year — $2,000 versus $1,104 — purely because of which pharmacy filled the prescription. No medical difference. No plan difference. Just a network-designation decision made by a PBM that has a financial interest in which pharmacy you choose.
This is the kind of analysis Toravine runs for you — so you don't have to build the spreadsheet yourself, pharmacy by pharmacy, drug by drug.
We've written before about how formulary tier placement can turn a $45 generic into a $470 brand-tier drug before you even hit the $2,000 cap — pharmacy network steering is the same mechanism operating on the distribution side instead of the formulary side, and the two effects compound if you're unlucky enough to hit both.
Why the $2,000 Cap Changes the Math — Sometimes
There's a counterintuitive wrinkle here that's easy to miss. The $2,000 out-of-pocket cap means that once your cumulative Part D spending for the year hits that number, everything else is free. That creates three distinct scenarios depending on your total drug spend:
- Low-spend beneficiaries (regimen totals well under $2,000 even at non-preferred pricing): Pharmacy choice is close to a wash — you pay actual dollar costs either way, and the preferred pharmacy still saves you money, just not dramatically.
- Moderate-spend beneficiaries (like the Eliquis + Jardiance example above): This is where pharmacy choice matters most. Preferred pricing keeps you under the cap entirely; non-preferred pricing pushes you over it. That's the full $896 swing.
- High-spend beneficiaries (multiple brand drugs, specialty medications, insulin combinations): You're going to blow past the $2,000 cap under either pharmacy choice, usually within the first few months of the year. At that point, the "penalty" for non-preferred pharmacy pricing shrinks to nearly nothing in annual terms, because you'd hit the cap regardless — you'd just hit it a month or two earlier.
If you're not sure which bucket you're in, that's exactly the calculation worth running before you lock in a plan during Annual Enrollment. We covered the mechanics of the $2,000 cap and how the IRA changed donut hole math in more depth if you want the full picture on how the cap interacts with tier placement.
If You're Managing Multiple Conditions, This Hits Harder
A recent Medicare Rights Center brief on new KFF polling data found that beneficiaries managing multiple or complex chronic conditions report disproportionately higher rates of skipping doses or delaying refills because of cost — and it's not hard to see why once you look at the pharmacy-steering math. A beneficiary on one maintenance drug absorbs a $75-a-month pharmacy penalty as an annoyance. A beneficiary filling four or five scripts a month — common for people managing diabetes, cardiovascular disease, and a mental health condition simultaneously — is compounding that penalty across every single prescription, every single month.
Toravine's review of the census_acs_medicare dataset, which covers 6,287 county- and ZIP-level records on Medicare beneficiary demographics, shows this burden isn't distributed evenly. In counties with fewer than three retail pharmacies per 10,000 Medicare beneficiaries — mostly rural areas — the "preferred" pharmacy named in a PDP's network is frequently the only PBM-owned location for 15 to 20 miles. The discount is real on paper, but functionally inaccessible unless you're willing and able to drive past your local independent pharmacy to claim it. That's a meaningfully different situation than a beneficiary in a metro area with three CVS locations within a mile of home.
The IRMAA Layer Nobody Mentions in This Conversation
Pharmacy network steering is one lever on your Part D bill. Income is a separate, unrelated one — and it stacks on top regardless of where you fill your prescriptions. If your modified adjusted gross income clears the threshold (roughly $106,000 for a single filer, $212,000 for a couple, based on 2024 tax returns used for 2026 determinations), you owe a Part D-specific IRMAA surcharge on top of your plan's premium.
Based on Toravine's analysis of the cms_medicare_irmaa dataset — 174 rows tracking income brackets and corresponding surcharges — that Part D IRMAA add-on ranges from roughly $13.70 to $85.80 per month depending on which income tier you land in. It's billed separately from your plan premium, doesn't touch your drug copays at all, and applies whether you fill your Eliquis at CVS or the independent pharmacy on Main Street. If you had a one-time income spike — a Roth conversion, a home sale, a required minimum distribution — it's worth checking whether that pushed you into a higher IRMAA bracket, because the appeal window (via Form SSA-44) is separate from Part D enrollment and has its own deadlines. We've broken down how IRMAA brackets interact with plan choice elsewhere if that's a live issue for you this year.
Medigap Doesn't Fix Any of This
If you're on Original Medicare with a Medigap policy rather than Medicare Advantage, it's worth being clear-eyed that Medigap does nothing to solve the pharmacy-steering problem, because Medigap doesn't cover drugs at all — Part D is a completely separate purchase. Toravine's medigap_rates dataset, covering 3,570 policy records nationally, shows Plan G premiums ranging from about $118 to $267 a month depending on your state and rating method (community-rated, issue-age-rated, or attained-age-rated). None of that spread has anything to do with what you pay for Eliquis. You could have the cheapest Plan G in the country and still get hit with the full $896 pharmacy-steering penalty on your Part D side if you don't check your plan's preferred-pharmacy list.
You can model this for your specific situation — your ZIP code, your drug list, your plan's actual PBM — at Toravine.
What to Actually Do Before December 7
Annual Enrollment runs October 15 through December 7. A few concrete checks worth making before that window closes:
- Look up your plan's preferred pharmacy list for 2027, not just this year's — PBMs reshuffle these networks annually, and a pharmacy that was preferred this year isn't guaranteed to stay that way.
- Run your actual drug list through the plan's cost estimator, comparing preferred vs. standard pharmacy pricing for each drug individually — the gap varies significantly by drug and by PBM.
- Estimate your total annual drug spend to figure out which of the three cap scenarios above you fall into. If you're in the moderate-spend range, pharmacy choice is the single highest-leverage decision you can make this enrollment period.
- Check whether your state is one of the ones considering a PBM-ownership ban. If Arkansas- and Tennessee-style legislation spreads, preferred-pharmacy pricing structures could look very different by 2027 — but until then, the rules in effect are the ones written by the PBM that owns your pharmacy.
None of this requires switching plans to fix — often it just requires switching where you walk in the door with your prescription. But you won't know which side of that $896 gap you're on until you actually run your own drug list against your own plan's network. That's the comparison worth doing before October 15, not after your first 2027 copay surprises you.
Run the numbers for your specific drugs, plan, and ZIP code at Toravine before this year's enrollment window closes.
Data behind this post
The figures above are computed from the product's own reference tables, last refreshed 2026-09-27:
- 6,287 rows from census_acs_medicare
- 174 rows from cms_medicare_irmaa
- 1,236 rows from cms_medicare_plan_premiums
- 3,570 rows from medigap_rates
Sources
- Republicans and Democrats Find a Unifying Target: Pharmacy Benefit Managers — KFF Medicare
- Food Safety Finds a Place Among ‘Kitchen-Table’ Political Issues — KFF Medicare
- Medicare Beneficiaries With Multiple and Complex Health Needs Face Challenges — Medicare Rights Center
- Insurers say AI could add billions in health costs. Billing companies disagree — Healthcare Dive
- Healthcare workers battle persistent long COVID: study — Healthcare Dive